Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To compare efficacy of bisoprolol and bisoprolol+metformin combination in patients with arterial hypertension (AH) and metabolic syndrome (MS).

Material and methods. 20 patients with AH and MS were involved in the study. They were randomized in 2 groups, 10 patients in each group. Patients of the 1st group received bisoprolol. Patients of the 2nd group received combination of bisoprolol and metformin. Blood pressure (BP), body mass index (BMI), carbohydrate metabolism, lipid profile, microalbuminuria (МАU) level was determined before, within and at the end of 24-week treatment.

Results. Both treatments resulted in similar reduction in BP. Reduction of BMI and insulin plasma concentration was more significant in patients received combined therapy. Both treatments improved lipid profile and reduced MAU.

Conclusion. Bisoprolol has positive effect on pathogenic mechanisms of AH and MS. Metformin additionally improves carbohydrate and lipid metabolism.

About the Authors

V. A. Nevzorova
Vladivostok State Medical University
Russian Federation

N. V. Zakcharchuk
Vladivostok State Medical University
Russian Federation

O. V. Nastradin
Vladivostok State Medical University
Russian Federation

O. G. Pomogalova
Vladivostok State Medical University
Russian Federation


1. Hansen B.C. The metabolic syndrome X. Ann N Y Acad Sci 1999;892:1- 24.

2. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24;683-9.

3. Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability European Group for the study of Insulin Resistance (EGIR). Drugs 1999;58:5-7.

4. Vanhala M.G., Pitkajaravi T.K., Kumpusalo E.J., Takala J.K. Metabolic syndrome in middle-aged Finnish population. J Cardiovasc Risk 1997; 4: 291-5.

5. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged Swedish men. JAMA 2002;288:2709-16.

6. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9.

7. Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. РМЖ 2001;(2): 56-60.

8. Соколов Е.И., редактор. Метаболический синдром. Пособие для терапевтов и кардиологов. М.: РКИ Соверо Пресс; 2005.

9. Fudjii S., Goto D., Zaman T., et al. Diminished fibrinolysis and thrombosis: clinical implication for accelerated atherosclerosis. J Atheroscler Thromb 1998;28:100-3.

10. Juhan-Vague I., Alessi M.S., Vague P. Thrombogenic and fibrinolitic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:371-80.

11. King D.E., Mainous A.G., Buchanan T.A., Pearson W.S. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 2003;26:1535-9.

For citation:

Nevzorova V.A., Zakcharchuk N.V., Nastradin O.V., Pomogalova O.G. BISOPROLOL AND METFORMIN IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME. Rational Pharmacotherapy in Cardiology. 2007;3(5):54-57. (In Russ.)

Views: 3057

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)